Transcriptomics

Dataset Information

0

Mitoxantrone-liposome sensitizes Flt3-ITD acute myeloid leukemia to gilteritinib treatment


ABSTRACT: FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in acute myeloid leukemia (AML), and is associated with a poor prognosis and high relapse rate. Gilteritinib, as a second-generation FLT3 inhibitor, is an important target drug in the treatment of FLT3-ITD AML patients, but it still faces the problems of drug resistance and reduced potency. In this study, we found that mitoxantrone-liposome can sensensitized gilteritinib and enhanced the therapeutic effect in vivo and in vitro. RNA-sequencing revealed that the combination treatment resulted in specific changes in gene expression, reduced drug resistance and the mechanism. Primary AML cells harvested from patients with FLT3-ITD AML showed a significant response to combination treatment in vitro. Our data suggest represents a novel and promising therapeutic strategy for FLT3-ITD AML patients and relapsed/refractory(R/R) AML.

ORGANISM(S): Homo sapiens

PROVIDER: GSE276384 | GEO | 2025/03/19

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| PRJNA1156893 | ENA
2024-06-14 | GSE244855 | GEO
2022-08-25 | PXD023123 | Pride
2022-07-07 | GSE199333 | GEO
2022-08-25 | PXD023125 | Pride
2022-09-21 | GSE185519 | GEO
2021-07-07 | GSE179421 | GEO
2021-07-22 | GSE180181 | GEO
2022-12-07 | MSV000090855 | MassIVE
2021-07-22 | GSE180180 | GEO